Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)

被引：0

作者：

Inhwan Hwang

Jeong Eun Kim

Jae Ho Jeong

Jin-Hee Ahn

Kyung Hae Jung

Byung Ho Son

Hak Hee Kim

Junyoung Shin

Hee Jin Lee

Gyungyub Gong

Sung-Bae Kim

机构：

[1] University of Ulsan College of Medicine,Department of Oncology, Asan Medical Center

[2] University of Ulsan College of Medicine,Department of Surgery, Asan Medical Center

[3] University of Ulsan College of Medicine,Department of Pathology, Asan Medical Center

[4] University of Ulsan College of Medicine,Department of Radiology, Asan Medical Center

[5] Eulji University School of Medicine,Department of Oncology, Daejeon Eulji Medical Center

来源：

Breast Cancer Research and Treatment | 2023年 / 201卷

关键词：

Neoadjuvant; AC followed by docetaxel; FEC followed by docetaxel; Operable breast cancer; Locally advanced breast cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：193 / 204

页数：11

共 11 条

[1] Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)
Hwang, Inhwan
Kim, Jeong Eun
Jeong, Jae Ho
Ahn, Jin-Hee
Jung, Kyung Hae
Son, Byung Ho
Kim, Hak Hee
Shin, Junyoung
Lee, Hee Jin
Gong, Gyungyub
Kim, Sung-Bae
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2023, 201 (02) : 193 - 204
[2] A randomized phase Ill trial of neoadjuvant sequential chemotherapy with 4 cycles of adriamycin plus cyclophosphamide followed by 4 cycles of docetaxel (AC4-D4) versus shorter 3 cycles of FEC followed by 3 cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-Shorter): First report of efficacy & toxicity profile
Kim, J. E.
Ahn, J-H
Jung, K. H.
Lee, H. J.
Gong, G-Y
Lee, E-M
Ha, E. J.
Son, B-H
Ahn, S-H
Ahn, S. D.
Kim, H-H
Shin, H. J.
Kim, S-B
[J]. CANCER RESEARCH, 2016, 76
[3] Neoadjuvant adriamycin plus cyclophosphamide followed by docetaxel (AC4-D4) vs 5-fluorouracil, epirubicin plus cyclophosphamide followed by docetaxel (FEC3-D3) in stage II or III operable breast cancer : Randomized phase III neo-shorter trial (NCT02001506)
Hwang, Inhwan
Kim, Jeong Eun
Jeong, Jae Ho
Ahn, Jin-Hee
Jung, Kyung Hae
Son, Byung Ho
Ahn, Sei-Hyun
Lee, Hee Jin
Gong, Gyungyub
Kim, Sung-Bae
[J]. CANCER RESEARCH, 2021, 81 (04)
[4] DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer
Ejlertsen, B.
Tuxen, M. K.
Jakobsen, E. H.
Jensen, M-B
Knoop, A. S.
Hoejris, I.
Ewertz, M.
Balslev, E.
Vestlev, P. M.
Kenholm, J.
Nielsen, D. L.
Bechmann, T.
Andersson, M.
Cold, S.
Nielsen, H. M.
Maae, E.
Arlsen, D. C.
Mouridsen, H. T.
[J]. CANCER RESEARCH, 2017, 77
[5] Five years analysis of the PACS 01 trial:: 6 cycles of FEC100 vs 3 cycles of FECI00 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer
Roché, H
Fumoleau, P
Spielmann, M
Canon, JL
Delozier, T
Kerbrat, P
Serin, D
Lortholary, A
de Ghislain, C
Viens, P
Bergerat, JP
Genève, J
Martin, AL
Asselain, B
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S16 - S16
[6] A Phase III Adjuvant Randomized Trial of 6 Cycles of 5-Fluorouracil - Epirubicine-Cyclophosphamide (FEC100) Versus 4 FEC 100 Followed by 4 Taxol (FEC-T) in Node Positive Breast Cancer Patients (Trial B2000)
Delbaldo, C.
Serin, D.
Mousseau, M.
Greget, S.
Audhuy, B.
Priou, F.
Berdah, J-F
Teissier, E.
Quinaux, E.
Piedbois, P.
[J]. CANCER RESEARCH, 2010, 70
[7] A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000)
Delbaldo, C.
Serin, D.
Mousseau, M.
Greget, S.
Audhuy, B.
Priou, F.
Berdah, J. F.
Teissier, E.
Laplaige, P.
Zelek, L.
Quinaux, E.
Buyse, M.
Piedbois, P.
[J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 23 - 30
[8] NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer
Samuel, Jacobs A.
Wilson, John W.
Bandos, Hanna
Elledge, Richard M.
Robidoux, Andre
Fehrenbacher, Louis
Ward, Patrick J.
Polikoff, Johnathan
Brufsky, Adam M.
Provencher, Louise
Paterson, Alexander H. G.
Hamm, John T.
Carolla, Robert L.
Baez-Diaz, Luis
Rastogi, Priya
Julian, Thomas B.
Wickerham, D. Lawrence
Swain, Sandra M.
Geyer, Charles E., Jr.
Mamounas, Eleftherios P.
Wolmark, Norman
[J]. CANCER RESEARCH, 2015, 75
[9] NSABP B-47: A phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of docetaxel plus cyclophosphamide or four cycles of doxorubicin plus cyclophosphamide followed by weekly paclitaxel) to chemotherapy plus trastuzumab in women with node-positive or high-risk, node-negative, HER2-low invasive breast cancer
Fehrenbacher, Louis
Jeong, Jong-Hyeon
Rastogi, Priya
Geyer, Charles E.
Paik, Soonmyung
Ganz, Patricia A.
Land, Stephanie R.
Costantino, Joseph P.
Swain, Sandra M.
Mamounas, Eleftherios P.
Wolmark, Norman
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[10] NSABP B-47: A Randomized Phase Ill Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.
Fehrenbacher, L.
Jeong, J-H
Rastogi, P.
Geyer, C. E.
Paik, S.
Ganz, P. A.
Land, S. R.
Costantino, J. P.
Swain, S. M.
Mamounas, E. P.
Wolmark, N.
[J]. CANCER RESEARCH, 2011, 71

← 1 2 →